Neoadjuvant chemotherapy with @entity136 and @entity3003 followed by concurrent chemoradiotherapy in locally advanced @entity189 of XXXX .

@entity1 @entity137 @entity66 @entity1494 @entity75 @entity3003 @entity5 @entity189 @entity150 @entity1606 @entity74 @entity1277 @entity925 @entity136
UNASSIGNED: 4715 Background: In locally advanced @entity189 of @entity1494 radiation therapy, either alone, or in combination with chemotherapy is the treatment of choice for @entity1 whose disease is not amenable to surgery. This study was carried out to evaluate the efficacy and @entity137 of Neoadjuvant chemotherapy with @entity136 and @entity3003 followed by concurrent chemoradiotherapy in locally advanced @entity150 . @entity1 AND METHODS: 22 @entity1 were enrolled. All @entity1 initially received 4 cycles of @entity136 and @entity3003 , after which response evaluation was done with CT scanning and ultrasonography. @entity1 with complete response (CR) and partial response (PR) received 2 more cycles followed by radical radiotherapy with weekly @entity136 as radiation sensitizer. Those who had @entity66 ( @entity66 ) or @entity74 ( @entity74 ) were given concurrent chemoradiotherapy after four cycles. RESULTS: Twenty @entity1 were males and two were females. The median age was 52 years (range 35-70 years). All @entity1 had histopathological @entity1606 . Eleven (50%) @entity1 had T3 lesion, 7(31.81%) had T4 and 4(18.18%) cases had @entity75 . Out of 22, 6(27.27%) @entity1 showed CR, and PR was seen in 9(40.90%) @entity1 . Four (18.18%) @entity1 had @entity66 whereas 3 @entity1 showed progression of the disease. Two cases out of four having @entity66 showed regression of @entity5 after concurrent chemoradiotherapy. No grade III/IV @entity137 was seen. Common @entity137 observed were Neutrogena, fatigue, @entity1277 and @entity925 . CONCLUSION: Neoadjuvant chemotherapy with @entity136 - @entity3003 followed by concurrent chemoradiotherapy is a well tolerable and effective treatment modality to achieve significant @entity5 response in locally advanced @entity150 . No significant financial relationships to disclose.
